Petosemtamab in combination with pembrolizumab interim data presented at 2024 ASCO® demonstrated robust 67% response rate among 24 evaluable patients
– First patients dosed in phase 3 trial evaluating petosemtamab monotherapy in 2/3L HNSCC, phase 2 trial evaluating petosemtamab in combination with standard chemotherapy in 2L mCRC, and phase 2 trial evaluating MCLA-129 in combination with chemotherapy in 2L+ EGFRm NSCLC
– Based on the Company’s current operating plan, existing cash, cash equivalents, including successful public offering raising $460M gross proceeds, and marketable securities expected to fund Merus’ operations into 2028
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.